Classifications: hormone; antidiabetic agent; insulin, rapid-acting; Therapeutic: antidiabetic; insulin rapid-acting
Prototype: Insulin injection
Pregnancy Category: C
100 U/mL injection
A recombinant insulin analog that is more rapidly absorbed than human insulin, with a more rapid onset and shorter duration
than regular human insulin.
Provides better blood glucose control than regular human insulin when given before a meal.
Treatment of diabetes mellitus.
Systemic allergic reactions; history of allergic reactions to insulin; hypoglycemia; pregnancy (category C).
Fever, hyperthyroidism, surgery or trauma; decreased insulin requirements due to diarrhea, nausea, or vomiting, malabsorption;
renal or hepatic impairment, hypokalemia.
Route & Dosage
Adult: SC 0.250.7 units/kg/d injected 510 min before each meal
- Note: Must give 510 min before a meal.
- Draw up insulin aspart first when mixing with NPH insulin. Give injection immediately after it is mixed. Do not give NPH
mixture by IV.
- Store refrigerated at 2°8° C (36°46° F); may be stored at room temperature, 15°30°
C (59°86° F) for up to 28 d. Do not expose to excessive heat or sunlight, and do not freeze.
Adverse Effects (≥1%)Body as a Whole:
Allergic reactions. Endocrine: Hypoglycemia
, hypokalemia. Skin:
Injection site reaction, lipodystrophy, pruritus, rash.
InteractionsDrug: oral antidiabetic agents
, ace inhibitors
, disopyramide, fluoxetine, mao inhibitors
, propoxyphene, salicylates
, sulfonamide antibiotics
may enhance hypoglycemia; corticosteroids
, niacin, danazol, diuretics
, sympathomimetic agents
, thyroid hormones
, isoniazid, somatropin
my decrease hypoglycemic effects; beta-blockers
, clonidine, lithium, alcohol
may either potentiate or weaken effects of insulin; pentamidine
may cause hypoglycemia
followed by hyperglycemia. Herbal: Garlic, ginseng
may potentiate hypoglycemic effects.
Rapidly absorbed from SC injection site. Onset:
15 min. Peak:
13 h. Duration:
35 h. Distribution:
Low protein binding. Metabolism:
In liver with some metabolism
in the kidneys. Half-Life:
Assessment & Drug Effects
- Monitor for S&S of hypoglycemia (see Appendix F). Initial hypoglycemic response begins within 15 min and peaks 4590
min after injection.
- Lab tests: Periodically monitor fasting blood glucose and HbA1C.
- Withhold drug and notify physician if patient is hypokalemic.
Patient & Family Education
- Do not inject into areas with redness, swelling, itching, or dimpling.
- Ingest some form of sugar (e.g., orange juice, dissolved table sugar, honey) if symptoms of hypoglycemia develop, and seek
- Check blood sugar as prescribed, especially postprandial values; notify physician of fasting blood glucose <80 and >120
- Notify the physician of any of the following: Fever, infection, trauma, diarrhea, nausea or vomiting. Dosage adjustment may
- Do not take any other medication unless approved by the physician.